When combined with clinical factors, blood biomarkers such as serum neurofilament light (NfL) and genetic status (GBA and APOE) have been shown to be beneficial in PD prognostic modeling, offering a stronger prediction of poor outcomes [141]. The gene discussed is NEFL; the disease is Parkinson disease.